{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:54:06Z","timestamp":1791089646858,"version":"4.1.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.bpg.2012.01.017","type":"journal-article","created":{"date-parts":[[2012,4,4]],"date-time":"2012-04-04T05:48:43Z","timestamp":1333518523000},"page":"85-95","source":"Crossref","is-referenced-by-count":23,"title":["Optimization of the use of Calcineurin inhibitors in liver transplantation"],"prefix":"10.1016","volume":"26","author":[{"given":"E.L.D.","family":"de Mare-Bredemeijer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.J.","family":"Metselaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpg.2012.01.017_bib1","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1056\/NEJM198912213212507","article-title":"Cyclosporine","volume":"321","author":"Kahan","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpg.2012.01.017_bib2","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.7164\/antibiotics.40.1256","article-title":"FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro","volume":"40","author":"Kino","year":"1987","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.bpg.2012.01.017_bib3","first-page":"1902","article-title":"Current status of FK 506 in liver transplantation","volume":"23","author":"Fung","year":"1991","journal-title":"Transplant Proc"},{"key":"10.1016\/j.bpg.2012.01.017_bib4","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJM199410273311702","article-title":"A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. The U.S. Multicenter FK506 Liver Study Group","volume":"331","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpg.2012.01.017_bib5","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/j.1600-6143.2006.01360.x","article-title":"Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis","volume":"6","author":"McAlister","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.bpg.2012.01.017_bib6","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/lt.20490","volume":"11","author":"Yoshida","year":"2005","journal-title":"Liver Transpl"},{"key":"10.1016\/j.bpg.2012.01.017_bib7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1600-6143.2008.02493.x","article-title":"Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the \u2018ReSpECT\u2019 study","volume":"9","author":"Neuberger","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.bpg.2012.01.017_bib8","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1034\/j.1600-6143.2003.00123.x","article-title":"T-cell allorecognition and transplant rejection: a summary and update","volume":"3","author":"Heeger","year":"2003","journal-title":"Am J Transplant"},{"key":"10.1016\/j.bpg.2012.01.017_bib9","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1074\/jbc.271.3.1274","article-title":"Identification of a physical interaction between calcineurin and nuclear factor of activated T cells (NFATp)","volume":"271","author":"Wesselborg","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bpg.2012.01.017_bib10","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1097\/00007890-200205150-00001","article-title":"Multiple pathways to allograft rejection","volume":"73","author":"Le Moine","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.bpg.2012.01.017_bib11","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/0952-7915(93)90135-F","article-title":"Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology","volume":"5","author":"Bierer","year":"1993","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.bpg.2012.01.017_bib12","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0952-7915(00)00130-8","article-title":"Chemokines and their receptors in allograft rejection","volume":"12","author":"Hancock","year":"2000","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.bpg.2012.01.017_bib13","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/00007691-199512000-00011","article-title":"Consensus document: therapeutic monitoring of tacrolimus (FK-506)","volume":"17","author":"Jusko","year":"1995","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.bpg.2012.01.017_bib14","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0090-9556(25)08793-8","article-title":"Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat","volume":"20","author":"Sattler","year":"1992","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bpg.2012.01.017_bib15","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S0090-9556(25)06862-X","article-title":"Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability","volume":"23","author":"Lampen","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bpg.2012.01.017_bib16","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/0140-6736(91)92302-I","article-title":"First-pass metabolism of cyclosporin by the gut","volume":"338","author":"Kolars","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2012.01.017_bib17","first-page":"940","article-title":"Measurement of FK 506 by HPLC and isolation and characterization of its metabolites","volume":"23","author":"Christians","year":"1991","journal-title":"Transplant Proc"},{"key":"10.1016\/j.bpg.2012.01.017_bib18","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1093\/clinchem\/42.9.1426","article-title":"Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant patients","volume":"42","author":"Gonschior","year":"1996","journal-title":"Clin Chem"},{"key":"10.1016\/j.bpg.2012.01.017_bib19","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/11317350-000000000-00000","article-title":"Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I","volume":"49","author":"Staatz","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bpg.2012.01.017_bib20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1067\/mcp.2001.113183","article-title":"The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups","volume":"69","author":"Mancinelli","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bpg.2012.01.017_bib21","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/clpt.1992.156","article-title":"Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: racial differences in bioavailability","volume":"52","author":"Lindholm","year":"1992","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bpg.2012.01.017_bib22","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1097\/00007890-199305000-00006","article-title":"The adverse impact of high cyclosporine. Clearance rates on the incidences of acute rejection and graft loss","volume":"55","author":"Lindholm","year":"1993","journal-title":"Transplantation"},{"key":"10.1016\/j.bpg.2012.01.017_bib23","first-page":"837","article-title":"Variations in bioavailability of cyclosporine and relationship to clinical outcome in renal transplant subpopulations","volume":"27","author":"Schroeder","year":"1995","journal-title":"Transplant Proc"},{"key":"10.1016\/j.bpg.2012.01.017_bib24","doi-asserted-by":"crossref","first-page":"378","DOI":"10.2165\/00002018-199411050-00005","article-title":"Clinical trials and transethnic pharmacology","volume":"11","author":"Kitler","year":"1994","journal-title":"Drug Saf"},{"key":"10.1016\/j.bpg.2012.01.017_bib25","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1021\/js9702168","article-title":"Influence of race or ethnicity on pharmacokinetics of drugs","volume":"86","author":"Johnson","year":"1997","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.bpg.2012.01.017_bib26","first-page":"489","article-title":"Ethnic differences in nifedipine kinetics: comparisons between Nigerians, Caucasians and South Asians","volume":"40","author":"Sowunmi","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bpg.2012.01.017_bib27","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2012.01.017_bib28","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1053\/gast.2003.50095","article-title":"Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study","volume":"124","author":"Samuel","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2012.01.017_bib29","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jhep.2004.04.023","article-title":"Prevention and treatment of hepatitis C virus recurrence after liver transplantation","volume":"41","author":"Garcia-Retortillo","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2012.01.017_bib30","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1053\/jhep.2003.50449","article-title":"Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes","volume":"38","author":"Watashi","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2012.01.017_bib31","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1053\/j.gastro.2005.06.031","article-title":"Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins","volume":"129","author":"Nakagawa","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2012.01.017_bib32","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.bbrc.2006.03.059","article-title":"Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811","volume":"343","author":"Goto","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bpg.2012.01.017_bib33","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1053\/j.gastro.2006.08.027","article-title":"Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha","volume":"131","author":"Henry","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2012.01.017_bib34","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/hep.21102","article-title":"The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro","volume":"43","author":"Paeshuyse","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2012.01.017_bib35","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1016\/j.transproceed.2008.07.006","article-title":"Effects of immunosuppressants on the progression of hepatitis C in hepatitis C virus-positive renal transplantation and the usefulness of interferon therapy","volume":"40","author":"Nanmoku","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1016\/j.bpg.2012.01.017_bib36","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/lt.21358","article-title":"Differential effects of calcineurin inhibitors, tacrolimus and cyclosporin a, on interferon-induced antiviral protein in human hepatocyte cells","volume":"14","author":"Hirano","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1016\/j.bpg.2012.01.017_bib37","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/lt.22032","article-title":"Calcineurin inhibitor tacrolimus does not interfere with the suppression of hepatitis C virus infection by interferon-alpha","volume":"16","author":"Pan","year":"2010","journal-title":"Liver Transpl"},{"key":"10.1016\/j.bpg.2012.01.017_bib38","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/lt.20532","article-title":"Cyclosporine suppresses hepatitis C\u00a0virus in vitro and increases the chance of a sustained virological response after liver transplantation","volume":"12","author":"Firpi","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1016\/j.bpg.2012.01.017_bib39","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1432-2277.2011.01254.x","article-title":"Efficacy, safety, and immunosuppressant adherence in stable liver transplant patients converted from a twice-daily tacrolimus-based regimen to once-daily tacrolimus extended-release formulation","volume":"24","author":"Beckebaum","year":"2011","journal-title":"Transpl Int"},{"key":"10.1016\/j.bpg.2012.01.017_bib40","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2165\/00003495-200363120-00006","article-title":"Tacrolimus: a further update of its use in the management of organ transplantation","volume":"63","author":"Scott","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.bpg.2012.01.017_bib41","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation","volume":"43","author":"Staatz","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bpg.2012.01.017_bib42","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/FTD.0b013e318198d092","article-title":"Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference","volume":"31","author":"Wallemacq","year":"2009","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.bpg.2012.01.017_bib43","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.transproceed.2004.12.222","article-title":"Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen","volume":"37","author":"Alloway","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.bpg.2012.01.017_bib44","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.transproceed.2004.11.086","article-title":"Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen","volume":"37","author":"Florman","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.bpg.2012.01.017_bib45","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1111\/j.1600-6143.2009.02794.x","article-title":"Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial","volume":"9","author":"Wlodarczyk","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.bpg.2012.01.017_bib46","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/lt.22211","article-title":"Pharmacokinetics for once-daily versus twice-daily tacrolimus formulations in de novo liver transplantation: a randomized, open-label trial","volume":"17","author":"Fischer","year":"2011","journal-title":"Liver Transpl"},{"key":"10.1016\/j.bpg.2012.01.017_bib47","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1016\/j.transproceed.2010.09.052","article-title":"Improvement of graft function after conversion to once daily tacrolimus of stable kidney transplant patients","volume":"42","author":"Tinti","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1016\/j.bpg.2012.01.017_bib48","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1097\/00007890-200112270-00012","article-title":"End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment","volume":"72","author":"Gonwa","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.bpg.2012.01.017_bib49","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/01.tp.0000258586.52777.4c","article-title":"Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs","volume":"83","author":"Flechner","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.bpg.2012.01.017_bib50","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa021744","article-title":"Chronic renal failure after transplantation of a nonrenal organ","volume":"349","author":"Ojo","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpg.2012.01.017_bib51","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/lt.22064","article-title":"Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age","volume":"16","author":"Tjon","year":"2010","journal-title":"Liver Transpl"},{"key":"10.1016\/j.bpg.2012.01.017_bib52","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S0168-8278(00)00077-5","article-title":"Increased cancer risk after liver transplantation: a population-based study","volume":"34","author":"Haagsma","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2012.01.017_bib53","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2337\/diacare.25.3.583","article-title":"Posttransplantation diabetes: a systematic review of the literature","volume":"25","author":"Montori","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bpg.2012.01.017_bib54","series-title":"Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003","first-page":"SS3","article-title":"New-onset diabetes after transplantation: 2003 International consensus guidelines","volume":"75","author":"Davidson","year":"2003"},{"key":"10.1016\/j.bpg.2012.01.017_bib55","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.ecl.2007.07.007","article-title":"New onset diabetes mellitus after solid organ transplantation","volume":"36","author":"Pham","year":"2007","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.bpg.2012.01.017_bib56","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0140-6736(94)91766-3","article-title":"Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2012.01.017_bib57","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1432-2277.2008.00800.x","article-title":"New-onset diabetes mellitus after solid organ transplantation","volume":"22","author":"Bodziak","year":"2009","journal-title":"Transpl Int"},{"key":"10.1016\/j.bpg.2012.01.017_bib58","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1097\/00007890-200109270-00015","article-title":"Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality","volume":"72","author":"Baid","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.bpg.2012.01.017_bib59","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/00004836-199801000-00009","article-title":"Higher incidence of diabetes in liver transplant recipients with hepatitis C","volume":"26","author":"Knobler","year":"1998","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.bpg.2012.01.017_bib60","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1053\/jhep.2000.8270","article-title":"Hepatitis C-related cirrhosis: a predictor of diabetes after liver transplantation","volume":"32","author":"Bigam","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2012.01.017_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1399-0012.2007.00739.x","article-title":"Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity","volume":"22","author":"Flechner","year":"2008","journal-title":"Clin Transplant"},{"issue":"Suppl. 7","key":"10.1016\/j.bpg.2012.01.017_bib62","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1034\/j.1399-0012.16.s7.7.x","article-title":"Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent","volume":"16","author":"Cotterell","year":"2002","journal-title":"Clin Transplant"},{"key":"10.1016\/j.bpg.2012.01.017_bib63","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1053\/jlts.2003.50183","article-title":"Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus","volume":"9","author":"Fairbanks","year":"2003","journal-title":"Liver Transpl"},{"key":"10.1016\/j.bpg.2012.01.017_bib64","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0041-1345(03)00082-4","article-title":"Sirolimus in patients after liver transplantation","volume":"35","author":"Kniepeiss","year":"2003","journal-title":"Transplant Proc"},{"key":"10.1016\/j.bpg.2012.01.017_bib65","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1053\/jlts.2003.50026","article-title":"Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients","volume":"9","author":"Nair","year":"2003","journal-title":"Liver Transpl"},{"key":"10.1016\/j.bpg.2012.01.017_bib66","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/lt.21116","article-title":"Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients","volume":"13","author":"Morard","year":"2007","journal-title":"Liver Transpl"},{"key":"10.1016\/j.bpg.2012.01.017_bib67","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/01.tp.0000261630.63550.41","article-title":"Sirolimus conversion in liver transplant recipients with renal dysfunction: a prospective, randomized, single-center trial","volume":"83","author":"Shenoy","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.bpg.2012.01.017_bib68","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1002\/lt.21314","article-title":"A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function","volume":"13","author":"Watson","year":"2007","journal-title":"Liver Transpl"},{"key":"10.1016\/j.bpg.2012.01.017_bib69","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/lt.21827","article-title":"Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial","volume":"15","author":"De Simone","year":"2009","journal-title":"Liver Transpl"},{"key":"10.1016\/j.bpg.2012.01.017_bib70","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/jlts.2003.50079","article-title":"Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications","volume":"9","author":"Dunkelberg","year":"2003","journal-title":"Liver Transpl"},{"key":"10.1016\/j.bpg.2012.01.017_bib71","doi-asserted-by":"crossref","first-page":"193S","DOI":"10.1016\/S0041-1345(03)00234-3","article-title":"Sirolimus in liver transplantation","volume":"35","author":"Trotter","year":"2003","journal-title":"Transplant Proc"},{"key":"10.1016\/j.bpg.2012.01.017_bib72","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/lt.20802","article-title":"12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus","volume":"12","author":"Levy","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1016\/j.bpg.2012.01.017_bib73","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1097\/01.tp.0000262607.95372.e0","article-title":"De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects","volume":"83","author":"Toso","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.bpg.2012.01.017_bib74","first-page":"521","article-title":"Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporine and FK 506, and effect on host-versus-graft and graft-versus-host reactions","volume":"23","author":"Morris","year":"1991","journal-title":"Transplant Proc"},{"key":"10.1016\/j.bpg.2012.01.017_bib75","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1517\/14656566.2.11.1903","article-title":"Sirolimus: a comprehensive review","volume":"2","author":"Kahan","year":"2001","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.bpg.2012.01.017_bib76","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1399-0012.2004.00188.x","article-title":"Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies","volume":"18","author":"Mathew","year":"2004","journal-title":"Clin Transplant"},{"key":"10.1016\/j.bpg.2012.01.017_bib77","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/01.TP.0000184006.43152.8D","article-title":"Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies","volume":"80","author":"Kauffman","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.bpg.2012.01.017_bib78","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1681\/ASN.2005090993","article-title":"Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation","volume":"17","author":"Campistol","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.bpg.2012.01.017_bib79","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm0202-128","article-title":"Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor","volume":"8","author":"Guba","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.bpg.2012.01.017_bib80","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1055\/s-2005-872520","article-title":"Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children","volume":"217","author":"Koehl","year":"2005","journal-title":"Klin Padiatr"},{"key":"10.1016\/j.bpg.2012.01.017_bib81","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.3748\/wjg.v11.i10.1420","article-title":"Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth","volume":"11","author":"Schumacher","year":"2005","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.bpg.2012.01.017_bib82","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1053\/jlts.2001.26510","article-title":"Orthotopic liver transplantation using low-dose tacrolimus and sirolimus","volume":"7","author":"McAlister","year":"2001","journal-title":"Liver Transpl"}],"container-title":["Best Practice & Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691812000182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691812000182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T09:16:29Z","timestamp":1742894189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691812000182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S1521691812000182"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2012.01.017","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}